We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
Cap. Flow
-$105M
Cap. Flow %
-4.06%
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$42.8M
2
ABBV icon
AbbVie
ABBV
+$22.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.8M
4
CELG
Celgene Corp
CELG
+$14.3M
5
NVO
Novo Nordisk
NVO
+$10.1M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$25.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$24.3M
3
AGN
Allergan plc
AGN
+$23.5M
4
GILD icon
Gilead Sciences
GILD
+$21.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Real Estate 2.87%
3 Miscellaneous 2.53%
4 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
26
Thermo Fisher Scientific
TMO
$237B
$26.2M 1.01%
137,968
-81,104
-37% -$15.5M
NBIX icon
27
Neurocrine Biosciences
NBIX
$15.3B
$25.2M 0.97%
325,067
-237,400
-42% -$16.2M
CNC icon
28
Centene
CNC
$33.8B
$23.2M 0.9%
460,316
– –
BMY icon
29
Bristol-Myers Squibb
BMY
$131B
$21.4M 0.83%
+349,121
New +$21.8M
IDXX icon
30
Idexx Laboratories
IDXX
$40.5B
$20.7M 0.8%
132,352
– –
CI icon
31
Cigna
CI
$75.3B
$20.3M 0.78%
100,002
– –
MCK icon
32
McKesson
MCK
$104B
$19.3M 0.75%
123,950
-18,850
-13% -$2.79M
XBI icon
33
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$19.2M 0.74%
226,460
– –
SRPT icon
34
Sarepta Therapeutics
SRPT
$2.12B
$18.6M 0.72%
334,400
-202,200
-38% -$10.7M
OHI icon
35
Omega Healthcare
OHI
$14.2B
$16M 0.62%
579,785
+121,169
+26% +$3.5M
COR icon
36
Cencora
COR
$61.2B
$15.4M 0.59%
167,307
-120,880
-42% -$10M
AZN icon
37
AstraZeneca
AZN
$253B
$15.4M 0.59%
221,300
– –
PVLA
38
Palvella Therapeutics
PVLA
$2.19B
$14.8M 0.57%
24,530
-10,940
-31% -$5.09M
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$31.9B
$14.6M 0.56%
114,966
– –
NVO
40
Novo Nordisk
NVO
$186B
$14.6M 0.56%
543,600
+396,400
+269% +$10.1M
SBRA icon
41
Sabra Healthcare REIT
SBRA
$5.16B
$13.6M 0.52%
724,606
+173,616
+32% +$3.45M
NVRO
42
DELISTED
NEVRO CORP.
NVRO
$13.4M 0.52%
194,621
– –
JAZZ icon
43
Jazz Pharmaceuticals
JAZZ
$15.8B
$13.3M 0.51%
98,421
-175,495
-64% -$24.3M
DPLO
44
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$12.9M 0.5%
640,492
+178,780
+39% +$3.52M
GSK icon
45
GSK
GSK
$100B
$12.7M 0.49%
287,200
– –
DHC
46
Diversified Healthcare Trust
DHC
$1.9B
$12.4M 0.48%
646,554
– –
XLRN
47
DELISTED
Acceleron Pharma
XLRN
$12M 0.46%
283,383
+223,729
+375% +$8.39M
WELL.PRI
48
DELISTED
Welltower Inc.
WELL.PRI
$12M 0.46%
200,000
– –
SGEN
49
DELISTED
Seagen Inc. Common Stock
SGEN
$12M 0.46%
223,700
– –
MPT
50
Medical Properties Trust
MPT
$2.11B
$11.8M 0.46%
858,586
-149,131
-15% -$2.02M
1
2
3 4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.

  • Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
  • Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
  • Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
  • Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
  • Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
  • Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.